Disposition of oral lisuride in Parkinson's disease.
The single and multiple oral dose plasma kinetics of lisuride were followed by a recently developed radioimmunoassay method in 11 patients with Parkinson's disease. A very wide range of plasma drug concentrations resulted from a single dose of 300 micrograms, as reflected in large interindividual differences in peak concentration (0.27 to 3.30 ng/ml) and AUC after the initial dose (43.1 to 617 ng X min/ml). Absorption was rapid, with a mean time to peak of 39 min. Only 0.05% of the dose was excreted unchanged in urine in 24 hr. There was a 110% increase in apparent oral clearance after 2 to 4 wk of treatment.
D000284:Administration, Oral; D000368:Aged; D001682:Biological Availability; D004873:Ergolines / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D008090:Lisuride / Q000378:metabolism* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D011863:Radioimmunoassay
D004873:Ergolines; D008090:Lisuride